Now showing items 1-4 of 4
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
(The British Pharmacological Society, 2009)
AIMS Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim was to develop an integrated population pharmacokinetic/pharmacogenetic model and investigate the impact of genetic variations, ...
Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans
(Lippincott Wilkins & Williams, 2010)
Abstract: Quinine is one of the most effective antimalarial drugs, although its clinical use is limited as a result of its narrow safety margin. Quinine is a substrate of the polymorphic p-glycoprotein and CYP3A4/3A5. This ...
In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype
(The British Pharmacological Society, 2010)
AIMS This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data to predict human efavirenz exposure after single and continuous dosing as well as the effects of concomitant ...
HIV/AIDS patients display lower relative bioavailability of Efavirenz than healthy subjects
(Adis Data Information BV., 2011)
Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and ...